Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy

Journal of Biomedical Nanotechnology

Volumn 13, Issue 2, 2017, Pages 192-203

  Chuang, Chih Hung ^a   Wu, Pao Chu ^a   Tsai, Teng Huang ^b   Fang, Yi Ping ^a   Tsai, Yi Hung ^a   Cheng, Ta Chun ^a   Huang, Chien Chaio ^a   Huang, Ming Yii ^a,c   Chen, Fang Ming ^d   Hsieh, Yuan Chin ^a   Lin, Wen Wei ^e   Tsai, Ming Jun ^f,g,h   Cheng, Tian Lu ^a,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h Cardiology Section   (Taiwan)

Author keywords

Camptothecin; Cancer Targeting Therapy; PH Sensitive Cationic PEGylated SLNs; Solid Lipid Nanoparticles

Indexed keywords

BODY FLUIDS; DISEASES; EFFICIENCY; NANOPARTICLES; POLYETHYLENE OXIDES; TUMORS;

CAMPTOTHECIN (CPT); CANCER-TARGETING; HEPATOCELLULAR CARCINOMA; HIGH ENTRAPMENT EFFICIENCIES; PEGYLATED; RETICULOENDOTHELIAL SYSTEMS; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES;

PH SENSORS;

CAMPTOTHECIN; MACROGOL; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC AGENT; LIPID; MACROGOL DERIVATIVE; NANOPARTICLE; PEGAMOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COLON CARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; HCT 116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LUNG CANCER CELL LINE; LUNG CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PLASMA HALF LIFE; TUMOR GROWTH; TUMOR LOCALIZATION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; MICE; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016009892     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2017.2338     Document Type: Article

References (51)

1. S. Cai, Q. H. Yang, T. R. Bagby, and M. L. Forrest, Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Advanced Drug Delivery Reviews 63, 901 (2011).
2. L. Harivardhan Reddy, R. K. Sharma, K. Chuttani, A. K. Mishra, and R. S. Murthy, Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dal-ton's lymphoma tumor bearing mice. J. Control. Release 105, 185 (2005).
3. A. Jain, A. Agarwal, S. Majumder, N. Lariya, A. Khaya, H. Agrawal, S. Majumdar, and G. P. Agrawal, Mannosylated solid lipid nanopar-ticles as vectors for site-specific delivery of an anti-cancer drug. J. Controlled Release 148, 359 (2010).
4. R. Paliwal, S. Rai, B. Vaidya, K. Khatri, A. K. Goyal, N. Mishra, A. Mehta, and S. P. Vyas, Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5, 184 (2009).
5. G. P. Zara, A. Bargoni, R. Cavalli, A. Fundaro, D. Vighetto, and M. R. Gasco, Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci. 91, 1324 (2002).
6. S. C. Yang, L. F. Lu, Y. Cai, J. B. Zhu, B. W. Liang, and C. Z. Yang, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59, 299 (1999).
7. G. P. Zara, R. Cavalli, A. Bargoni, A. Fundaro, D. Vighetto, and M. R. Gasco, Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target 10, 327 (2002).
8. A. J. Almeida and E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59, 478 (2007).
9. T. Takino, K. Konishi, Y. Takakura, and M. Hashida, Long circulating emulsion carrier systems for highly lipophilic drugs. Biol. Pharm. Bull. 17, 121 (1994).
10. T. G. Redgrave, V. Rakic, B. C. Mortimer, and J. C. Mamo, Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins from plasma. Studies with lipid emulsions in rats. Biochim. Biophys. Acta 1126, 65 (1992).
11. C. Bocca, O. Caputo, R. B. Cavalli, L. Gabriel, A. Miglietta, and M. R. Gasco, Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int. J. Pharm. 175, 185 (1998).
12. Y. P. Fang, P. C. Wu, Y. B. Huang, C. C. Tzeng, Y. L. Chen, Y. H. Hung, M. J. Tsai, and Y. H. Tsai, Modification of polyethylene gly-col onto solid lipid nanoparticles encapsulating a novel chemother-apeutic agent (PK-L4) to enhance solubility for injection delivery. Int. J. Nanomedicine 7, 4995 (2012).
13. F. Wan, J. You, Y. Sun, X. G. Zhang, F. D. Cui, Y. Z. Du, H. Yuan, and F. Q. Hu, Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): Preparation and evaluation in vitro. Int. J. Pharm. 359, 104 (2008).
14. M. Uner and G. Yener, Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomedicine 2, 289 (2007).
15. K. Tabatt, M. Sameti, C. Olbrich, R. H. Muller, and C. M. Lehr, Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur. J. Pharm. Biopharm. 57, 155 (2004).
16. N. Pedersen, S. Hansen, A. V. Heydenreich, H. G. Kristensen, and H. S. Poulsen, Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur. J. Pharm. Biopharm. 62, 155 (2006).
17. C. Olbrich, U. Bakowsky, C. M. Lehr, R. H. Muller, and C. Kneuer, Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release 77, 345 (2001).
18. M. L. Gonzalez-Rodriguez and A. M. Rabasco, Charged liposomes as carriers to enhance the permeation through the skin. Expert Opin. Drug Deliv. 8, 857 (2011).
19. Y. Chen, L. Zhou, L. Yuan, Z. H. Zhang, X. Liu, and Q. Wu, Formu-lation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int. J. Nanomedicine 7, 3023 (2012).
20. X. Z. Yang, J. Z. Du, S. Dou, C. Q. Mao, H. Y. Long, and J. Wang, Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 6, 771 (2012).
21. E. Rostami, S. Kashanian, A. H. Azandaryani, H. Faramarzi, J. E. Dolatabadi, and K. Omidfar, Drug targeting using solid lipid nanoparticles. Chem. Phys. Lipids 181, 56 (2014).
22. S. V. Mussi, R. C. Silva, M. C. Oliveira, C. M. Lucci, R. B. Azevedo, and L. A. Ferreira, New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur. J. Pharm. Sci. 48, 282 (2013).
23. S. Kashanian, A. H. Azandaryani, and K. Derakhshandeh, New surface-modified solid lipid nanoparticles using N-glutaryl phos-phatidylethanolamine as the outer shell. Int. J. Nanomedicine 6, 2393 (2011).
24. X. Z. Yang, X. J. Du, Y. Liu, Y. H. Zhu, Y. Z. Liu, Y. P. Li, and J. Wang, Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy. Adv. Mater. 26, 931 (2014).
25. H. Maeda, The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189 (2001).
26. E. Ruoslahti, S. N. Bhatia, and M. J. Sailor, Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188, 759 (2010).
27. C. H. Kao, J. Y. Wang, K. H. Chuang, C. H. Chuang, T. C. Cheng, Y. C. Hsieh, Y. L. Tseng, B. M. Chen, S. R. Roffler, and T. L. Cheng, One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPE-Gylated nanoparticles. Biomaterials 35, 9930 (2014).
28. S. H. Jang, M. G. Wientjes, D. Lu, and J. L. Au, Drug delivery and transport to solid tumors. Pharm. Res. 20, 1337 (2003).
29. F. Yuan, M. Leunig, S. K. Huang, D. A. Berk, D. Papahadjopoulos, and R. K. Jain, Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352 (1994).
30. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751 (2007).
31. Y. L. Zhang, Z. H. Zhang, T. Y. Jiang, W. Ayman, L. Jing, H. X. Lv, and J. P. Zhou, Cell uptake of paclitaxel solid lipid nanoparti-cles modified by cell-penetrating peptides in A549 cells. Pharmazie 68, 47 (2013).
32. L. Nobs, F. Buchegger, R. Gurny, and E. Allemann, Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 93, 1980 (2004).
33. M. Abercrombie and E. J. Ambrose, The surface properties of cancer cells: A review. Cancer Res. 22, 525 (1962).
34. I. Dobrzynska, B. Szachowicz-Petelska, B. Darewicz, and Z. A. Figaszewski, Characterization of human bladder cell membrane during cancer transformation. J. Membr. Biol. 248, 301 (2015).
35. M. Marquez, S. Nilsson, L. Lennartsson, Z. Liu, T. Tammela, M. Raitanen, and A. R. Holmberg, Charge-dependent targeting: Results in six tumor cell lines. Anticancer Res. 24, 1347 (2004).
36. E. Blanco, H. Shen, and M. Ferrari, Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941 (2015).
37. F. Braet, E. Wisse, P. Bomans, P. Frederik, W. Geerts, A. Koster, L. Soon, and S. Ringer, Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions. Microsc. Res. Tech. 70, 230 (2007).
38. Y. P. Fang, C. H. Chuang, P. C. Wu, Y. B. Huang, C. C. Tzeng, Y. L. Chen, Y. T. Liu, Y. H. Tsai, and M. J. Tsai, Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: Characterization and pharmacokinetics. Drug Des. Devel. Ther. 10, 1019 (2016).
39. A. Calcinotto, P. Filipazzi, M. Grioni, M. Iero, A. De Milito, A. Ricupito, A. Cova, R. Canese, E. Jachetti, M. Rossetti, V. Huber, G. Parmiani, L. Generoso, M. Santinami, M. Borghi, S. Fais, M. Bellone, and L. Rivoltini, Modulation of microenvironment acidity reverses energy in human and murine tumor-infiltrating T lym-phocytes. Cancer Res. 72, 2746 (2012).
40. C. R. Justus, L. Dong, and L. V. Yang, Acidic tumor microenvi-ronment and pH-sensing G protein-coupled receptors. Front Physiol. 4, 354 (2013).
41. P. Vaupel, F. Kallinowski, and P. Okunieff, Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 49, 6449 (1989).
42. D. Momekova, S. Rangelov, and N. Lambov, Long-circulating, pH-sensitive liposomes. Methods Mol. Biol. 605, 527 (2010).
43. M. S. Hong, S. J. Lim, Y. K. Oh, and C. K. Kim, pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J. Pharm. Pharmacol. 54, 51 (2002).
44. M. C. de Oliveira, V. Rosilio, P. Lesieur, C. Bourgaux, P. Couvreur, M. Ollivon, and C. Dubernet, pH-sensitive liposomes as a carrier for oligonucleotides: A physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in excess water. Biophys. Chem. 87, 127 (2000).
45. J. O'Leary and F. M. Muggia, Camptothecins: A review of their development and schedules of administration. Eur. J. Cancer 34, 1500 (1998).
46. C. J. Thomas, N. J. Rahier, and S. M. Hecht, Camptothecin: Current perspectives. Bioorg. Med. Chem. 12, 1585 (2004).
47. Q. Y. Li, Y. G. Zu, R. Z. Shi, and L. P. Yao, Review camptothecin: Current perspectives. Curr. Med. Chem. 13, 2021 (2006).
48. Z. M. Prijovich, K. C. Chen, and S. R. Roffler, Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy. Mol. Cancer Ther. 8, 940 (2009).
49. R. G. Azrak, J. Yu, L. Pendyala, P. F. Smith, S. Cao, X. Li, W. D. Shannon, F. A. Durrani, H. L. McLeod, and Y. M. Rustum, Irinote-can pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. Mol. Cancer Ther. 4, 843 (2005).
50. H. Bunjes, M. Drechsler, M. H. Koch, and K. Westesen, Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharm. Res. 18, 287 (2001).
51. Z. R. Huang, S. C. Hua, Y. L. Yang, and J. Y. Fang, Development and evaluation of lipid nanoparticles for camptothecin delivery: A comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol. Sin. 29, 1094 (2008).